Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Updated Food Recall Warning (Allergen) - Certain RXBAR brand Protein Bars recalled due to undeclared peanut


Product photos are available at: https://bit.ly/2Dk1LSo

OTTAWA, Feb. 8, 2019 /CNW/ - The food recall warning issued on January 15, 2019 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation.

Industry is recalling certain RXBAR brand Protein Bars from the marketplace because they may contain peanut which is not declared on the label. People with an allergy to peanut should not consume the recalled products described below. 

The following products have been sold nationally through Internet sales (www.amazon.ca and possibly other websites) as well as possibly through retail.

Recalled products

 

Brand

Product

Size

UPC

Codes

RXBAR

Protein Bar ? Blueberry

624 g (12 x 52 g)

8 57777 00426 3

Best By dates between

03 21 2019 to 05 21 2019 and 07 07 2019 to 09 29 2019

RXBAR

Protein Bar ? Blueberry

52 g

8 57777 00419 5

Best By dates between

03 21 2019 to 05 21 2019 and 07 07 2019 to 09 29 2019

RXBAR

Protein Bar ? Chocolate Sea Salt

624 g (12 x 52 g)

8 57777 00430 0

Best By dates between

03 04 2019 to 09 11 2019 and Best By 10 11 2019

RXBAR

Protein Bar ? Chocolate Sea Salt

52 g

8 57777 00423 2

Best By dates between

03 04 2019 to 09 11 2019 and Best By 10 11 2019

RXBAR

Protein Bar ? Coconut Chocolate

624 g (12 x 52 g)

8 57777 00428 7

Best By dates between

03 01 2019 to 10 13 2019

RXBAR

Protein Bar ? Coconut Chocolate

52 g

8 57777 00421 8

Best By dates between

03 01 2019 to 10 13 2019

RXBAR

Protein Bar ? Mint Chocolate

624 g (12 x 52 g)

8 57777 00434 8

Best By dates between

03 02 2019 to 04 18 2019 and 07 26 2019 to 08 09 2019

RXBAR

Protein Bar ? Mint Chocolate

52 g

8 57777 00433 1

Best By dates between

03 02 2019 to 04 18 2019 and 07 26 2019 to 08 09 2019

 

What you should do

Check to see if you have recalled products in your home. Recalled products should be thrown out or returned to the point of purchase.

If you have an allergy to peanut, do not consume the recalled products as they may cause a serious or life-threatening reaction.

Background

This recall was triggered by a recall in another country. The CFIA is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.

The CFIA is verifying that industry is removing recalled product from the marketplace.

Reactions

There have been no reported reactions associated with the consumption of these products in Canada.

More information

 

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 11:40
The "Musculoskeletal Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the...

at 11:30
The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024....



News published on and distributed by: